Longeveron Inc. experienced a challenging first quarter in 2025, with total revenues decreasing to $381,000 from $548,000 in the prior year. The company's net loss widened to $5,011,000, compared to $4,058,000 in Q1 2024, driven by increased operating expenses, particularly in general and administrative costs and research and development. The decrease in revenue was primarily attributed to lower participant demand for the Bahamas Registry Trial, despite an increase in contract manufacturing revenue.
Total revenues decreased by 30% to $381,000 in Q1 2025 from $548,000 in Q1 2024.
Net loss increased by 23% to $5,011,000 in Q1 2025 from $4,058,000 in Q1 2024.
General and administrative expenses rose by 34% to $2,941,000, mainly due to increased personnel and equity-based compensation costs.
Research and development expenses increased by 13% to $2,515,000, driven by higher personnel and patent-related costs, despite a decrease in clinical trial expenses.
Longeveron anticipates increased operating expenses and capital expenditure requirements throughout calendar 2025 due to BLA enabling activities for HLHS and manufacturing readiness. The company intends to seek additional financing and non-dilutive funding options to support these initiatives.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance